On January 4, 2018 Cue Biopharma, Inc., (NASDAQ: CUE) an immunotherapy company developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system to treat cancer and autoimmune diseases, reported that it will be featured as a presenting company at the upcoming 10th Annual Biotech Showcase Conference on January 9, 2018, in San Francisco, CA (Press release, Cue Biopharma, JAN 4, 2018, View Source [SID1234522915]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Presentation details:

Date: Tuesday, January 9, 2018

Time: 11:15 am PT

Duration: 15 minutes

Location: Franciscan Room B at the Ballroom Level of the Hilton San Francisco Union Square

Daniel Passeri, M.Sc., J.D., President and Chief Executive Officer of Cue Biopharma, will provide an overview of the Company’s technology platform and overall development strategy and give updates on key programs, including anticipated development milestones.

On January 4, 2018 Myovant Sciences (NYSE: MYOV), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for women’s health and endocrine diseases, reported that Lynn Seely, M.D., President and Chief Executive Officer of Myovant Sciences, will present at the 36th Annual J.P. Morgan Healthcare Conference in San Francisco, California on Wednesday January 10, 2018 at 2:30 p.m. PT (Press release, Myovant Sciences, JAN 4, 2018, http://investors.myovant.com/news-releases/2018/01-04-2018-133105307 [SID1234522891]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The event will be webcast live and may be accessed via the Events page under the Investors and Media section of Myovant’s website at www.myovant.com. Please connect to the company’s website at least 15 minutes prior to the presentation to ensure adequate time for any software download that may be required to listen to the webcast. A replay will also be available at the same location for 30 days following the conference.

On January 4, 2018 Syros Pharmaceuticals (NASDAQ: SYRS), a biopharmaceutical company pioneering the development of medicines to control the expression of genes, reported that its Chief Executive Officer, Nancy Simonian, M.D., will present a corporate overview, including 2018 objectives, at the 36th Annual J.P. Morgan Healthcare Conference (Press release, Syros Pharmaceuticals, JAN 4, 2018, View Source [SID1234522895]). Details are as follows:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

36th Annual J.P. Morgan Healthcare Conference
Date: Thursday, January 11
Time: 10:30 a.m. PST (1:30 p.m. EST)
Location: Westin St. Francis Hotel, 335 Powell St., San Francisco, CA

The presentation will be followed by a question and answer session.

A live webcast of the presentation and question and answer session will be available on the Investors & Media section of the Syros website at www.syros.com. An archived replay of the webcast will be available for approximately 30 days following the presentation.

On January 4, 2018 Aveo Presented Corporate Presentation Slide Deck dated January 2018 (Presentation, AVEO, JAN 4, 2018, View Source [SID1234522920]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On January 4, 2019 Alligator Bioscience (Nasdaq Stockholm: ATORX), a biotechnology company developing tumor-directed immunotherapies, reported that the company is scheduled to present at the 10th Annual Biotech Showcase conference held 8-10 January, 2018 in San Francisco, US (Press release, Alligator Bioscience, JAN 4, 2018, View Source [SID1234538682]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Chief Executive Officer Per Norlén will give an update on the company’s clinical stage project ADC-1013, out-licensed to Janssen Biotech Inc., as well as the near-clinical bispecific antibody ATOR-1015 and the preclinical projects ALG.APV-527 and ATOR-1017.

The presentation will take place on 8 January, at 10:30 a.m. PST /8 Jan 7:30 p.m. CET. The audio and slide presentation will be webcasted live and can be accessed via the Alligator web site. To access the presentation, live and replay, please go to View Source;tp_key=101995f0f8.

For further information, please contact:
Cecilia Hofvander, Director Investor Relations & Communications
Phone +46 46 286 44 95
E-mail: [email protected].

The information was submitted for publication, through the agency of the contact person set out above, at 11:00 a.m. CET on 4 January 2018.